Know Cancer

or
forgot password

A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)


N/A
18 Years
N/A
Not Enrolling
Both
Bladder Cancer, CIS

Thank you

Trial Information

A PROSPECTIVE REGISTRY TO ASSESS THE EFFECTIVENESS AND LOCAL TOLERABILITY OF INTRAVESICAL VALRUBICIN IN SUBJECTS WITH NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)


Inclusion Criteria:



- Males and females 18 years of age and older

- Diagnosed with NMIBC

- Prescribed intravesical valrubicin to treat NMIBC

- Understood and signed Informed Consent to participate

Exclusion Criteria:

- None

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Authority:

United States: Institutional Review Board

Study ID:

EN3329-402

NCT ID:

NCT01314664

Start Date:

May 2011

Completion Date:

July 2013

Related Keywords:

  • Bladder Cancer
  • CIS
  • Non-Muscle Invasive Bladder Cancer
  • CIS
  • BCG Refractory
  • Urinary Bladder Neoplasms

Name

Location

Vanderbilt University Medical CenterNashville, Tennessee  37232-2516
Urology Associates of North TexasArlington, Texas  76015
Urology Clinics of North TexasDallas, Texas  75231
BCG OncologyPhoenix, Arizona  85032
Urologic Consultants of SE PABala Cynwyd, Pennsylvania  19004
Delaware Valley UrologySewell, New Jersey  08080
Urology Research NetworkHialeah, Florida  33149
Advanced Urology Association of FloridaVero Beach, Florida  32960
Kansas City Urology CareOverland Park, Kansas  66211
Long Island Urological AssociatesBethpage, New York  11714